By Chris Wack
Regenxbio shares were 13% higher at $8.79, after the company said it saw positive interim data from two new patients in a Phase I/II trial of RGX-202, a differentiated investigational gene therapy for Duchenne muscular dystrophy.
The company said the new data from the ages 1 to 3 cohort builds on the favorable safety and efficacy profile seen in ages 4 and older.
Regenxbio said it plans to continue to advance the trial toward completing enrollment this year and BLA submission mid-2026.
In a patient aged 3 at dosing, microdystrophin expression was measured to be 122.3% compared to control. In a patient aged 7 years old, RGX-202 microdystrophin expression was measured to be 31.5% compared to control.
The company said that as of Feb. 21, RGX-202 was well tolerated with no serious adverse events and no adverse events of special interest. Common drug-related adverse events included nausea, vomiting and fatigue. All were resolved and are typically anticipated with gene therapy administration.
The stock hit its 52-week low of $5.62 on March 4, and is down 61% in the past 12 months.
Write to Chris Wack at chris.wack@wsj.com
(END) Dow Jones Newswires
March 19, 2025 10:15 ET (14:15 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.